Previous close | 6,217.15 |
Open | 6,239.60 |
Bid | 6,253.55 x 0 |
Ask | 6,259.20 x 0 |
Day's range | 6,181.70 - 6,310.00 |
52-week range | 4,383.40 - 6,505.50 |
Volume | |
Avg. volume | 14,221 |
Market cap | 1.041T |
Beta (5Y monthly) | 0.34 |
PE ratio (TTM) | 19.96 |
EPS (TTM) | 313.34 |
Earnings date | 07 May 2024 |
Forward dividend & yield | 40.00 (0.64%) |
Ex-dividend date | 11 Jul 2023 |
1y target est | 2,581.68 |
Centhaquine is a first-of-its-kind resuscitative agent to treat hypovolemic shock by increasing stroke volume and cardiac output due to an increase in (preload) venous blood return to the heart and a decrease in (afterload) due to arterial dilatationIndia is the first global territory where Centhaquine is being launched immediately WILLOWBROOK, Ill., March 22, 2024 (GLOBE NEWSWIRE) -- Pharmazz, Inc. ("Pharmazz"), a biopharmaceutical company developing and commercializing drug products to treat c
HYDERABAD, India, March 19, 2024--Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company, announced the launch of Versavo® (bevacizumab) in the United Kingdom (UK).
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.